MSTN and Cachexia: The identification of several components of the myostatin-signalling pathway had important implications with respect for testing the therapeutic value of a myostatin antagonist in muscle wasting disorders such as Duchenne muscular dystrophy [22,23] cachexia and age-related sarcopenia [24-26].